Fortis Therapeutics


Fortis Therapeutics is an immuno-oncology biotechnology company focused on the discovery and development of antibody-drug conjugate therapies that target the transmembrane immune modulatory receptor CD46. The company develops tumor-selective antibodies identified using tumor cell–based selection methods, conjugates them to cytotoxic payloads via established chemistry platforms, and advances candidates through preclinical studies and Phase 1 clinical trials. Fortis was founded on technology licensed from an academic laboratory and has executed multiple series A financings to support clinical development.

Industries

biotechnology
oncology
therapeutics

Nr. of Employees

small (1-50)

Fortis Therapeutics

La Jolla, California, United States, North America


Patents

Immunoconjugates targeting CD46 and methods of use thereof

US-12144888-B2

View Details

Engineered CD46-specific effector cells and uses thereof in the treatment of cancer

US-12049511-B2

View Details

Immunoconjugates targeting CD46 and methods of use thereof

US-11484604-B2

View Details

Products

Antibody-drug conjugate targeting CD46 (lead clinical candidate)

A fully human antibody recognizing a tumor-specific epitope on the immune modulatory receptor CD46, conjugated to a cytotoxic payload; advanced through preclinical testing and into Phase 1 clinical trials for late-stage prostate cancer and multiple myeloma.

FOR46

FOR46 is an antibody-drug conjugate targeting CD46, designed to recognize a tumor-specific epitope on CD46 and deliver a potent payload to kill tumor cells.


Services

Partnered preclinical and translational projects with academic and philanthropic organizations to support target validation and clinical translation.

Expertise Areas

  • Antibody-drug conjugate development
  • Immuno-oncology
  • Preclinical efficacy and safety evaluation
  • Phase 1 clinical trial management
  • Show More (4)

Key Technologies

  • Antibody-drug conjugates (ADCs)
  • Tumor cell–based antibody selection (in situ/tissue microenvironment)
  • Payload conjugation chemistry
  • In vitro cytotoxicity assays
  • Show More (3)

News & Updates

Announcement of a $40 million financing to advance the company's CD46-targeting ADC into clinical trials for multiple myeloma and metastatic castration-resistant prostate cancer.

Announcement of an $18 million Series A financing to support development of antibody-drug conjugate therapies for late-stage cancers.

Announcement that the FDA cleared two IND applications for the company's lead ADC program to treat metastatic castration-resistant prostate cancer and late-stage multiple myeloma.

Two investigational new drug applications cleared by the U.S. FDA enabling clinical trials in prostate cancer and multiple myeloma.

Multiple series A financings announced to fund clinical development (notably $18M and $40M rounds).


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.